Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 1,520 Shares

Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith sold 1,520 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $19.11, for a total value of $29,047.20. Following the completion of the sale, the general counsel directly owned 43,305 shares in the company, valued at approximately $827,558.55. The trade was a 3.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jason Drew Smith also recently made the following trade(s):

• On Monday, July 28th, Jason Drew Smith sold 7,522 shares of Urogen Pharma stock. The shares were sold at an average price of $19.14, for a total value of $143,971.08.

Urogen Pharma Stock Performance

URGN stock opened at $20.69 on Wednesday. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $21.71. The stock’s 50 day moving average price is $17.85 and its 200 day moving average price is $12.68. The firm has a market cap of $957.12 million, a P/E ratio of -6.23 and a beta of 1.10.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The business had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. On average, research analysts predict that Urogen Pharma will post -3.12 earnings per share for the current year.

Institutional Trading of Urogen Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in URGN. The Manufacturers Life Insurance Company increased its holdings in Urogen Pharma by 178.1% in the 4th quarter. The Manufacturers Life Insurance Company now owns 37,486 shares of the company’s stock valued at $399,000 after purchasing an additional 24,006 shares in the last quarter. Northern Trust Corp boosted its position in Urogen Pharma by 8.1% in the 4th quarter. Northern Trust Corp now owns 310,074 shares of the company’s stock valued at $3,302,000 after buying an additional 23,345 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Urogen Pharma by 9.3% in the 4th quarter. Ameriprise Financial Inc. now owns 49,153 shares of the company’s stock valued at $523,000 after buying an additional 4,188 shares during the last quarter. Bank of America Corp DE boosted its position in Urogen Pharma by 9.0% in the 4th quarter. Bank of America Corp DE now owns 72,472 shares of the company’s stock valued at $772,000 after buying an additional 5,983 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in Urogen Pharma by 61.6% in the 4th quarter. Deutsche Bank AG now owns 31,263 shares of the company’s stock valued at $333,000 after buying an additional 11,916 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

URGN has been the subject of several analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Urogen Pharma in a report on Tuesday, August 5th. Piper Sandler initiated coverage on Urogen Pharma in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 price target for the company. Guggenheim reiterated a “buy” rating and issued a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. HC Wainwright cut their price target on Urogen Pharma from $50.00 to $40.00 and set a “buy” rating for the company in a report on Monday, August 11th. Finally, Scotiabank reiterated an “outperform” rating on shares of Urogen Pharma in a report on Friday, June 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $32.00.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.